Gilead CFO sells 3,000 shares in planned trade

Gilead Sciences’ Chief Financial Officer Andrew D. Dickinson sold 3,000 shares of common stock at $144.23 per share in an open-market transaction.

Accepted by SEC EDGAR 03/17/2026 - 06:14 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Gilead Sciences’ Chief Financial Officer Andrew D. Dickinson sold 3,000 shares of common stock at $144.23 per share in an open-market transaction. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on August 29, 2024. Following this trade, he directly holds 179,191 shares of Gilead common stock.

Insider Trade Summary 10b5-1

Net Seller: 3,000 shares

Net Sell 1 txn

Insider Dickinson Andrew D

Role Chief Financial Officer

Sold 3,000 shs ($433K)

Share of Position Sold 1.6%

Type	Security	Shares	Price	Value
Sale	Common Stock	3,000	$144.23	$433K

Holdings After Transaction: Common Stock — 179,191 shares (Direct)

Holdings Before and After: Common Stock, 182,191 to 179,191 shares (Direct)

Other Insiders: 2 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (1)

1. F1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Gilead (GILD) CFO Andrew Dickinson do in this Form 4 filing?

Gilead CFO Andrew Dickinson sold 3,000 shares of common stock at $144.23 per share. The transaction was an open-market sale and was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 29, 2024.

How many Gilead (GILD) shares does the CFO hold after this sale?

After selling 3,000 shares, Gilead CFO Andrew Dickinson directly holds 179,191 shares of common stock. This figure reflects his position immediately following the reported open-market sale under his Rule 10b5-1 trading plan.

At what price were the Gilead (GILD) shares sold by the CFO?

The 3,000 Gilead shares were sold at $144.23 per share in an open-market transaction. This price represents the sale price disclosed, providing a clear view of the value realized in this specific Form 4 transaction.

Was the Gilead (GILD) CFO’s stock sale part of a trading plan?

Yes. The Form 4 states the transaction was made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. Such plans pre-schedule trades, indicating the sale’s timing was determined in advance rather than on an ad hoc basis.

Does the Gilead (GILD) Form 4 report any option exercises or derivative trades?

No derivative transactions or option exercises are reported in this Form 4. The filing shows only a single non-derivative open-market sale of 3,000 shares of common stock, with no remaining derivative positions listed in the derivative summary.

Is the Gilead (GILD) CFO’s share sale classified as a buy or sell transaction?

The transaction is classified as a sale. The Form 4 identifies it with code “S” for a sale in the open market or private transaction, and the normalized data flags the transaction direction as sell, reflecting a net disposition of 3,000 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dickinson Andrew D

(Last) (First) (Middle)

GILEAD SCIENCES, INC.

333 LAKESIDE DRIVE

(Street)

FOSTER CITY CA 94404

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/16/2026		S(1)		3,000	D	$144.23	179,191	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

Remarks:

	/s/ Amy Kim by Power of Attorney for Andrew D. Dickinson	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.